Research Article of International Journal of Bioscience and Medicine
Prevalence and Associated Factors of Antiepileptic Drugnonadherence Among Epileptic Patients Attending at Out Patient Departement of Dilla University Referral Hospital, Dilla,gedeo,snnpr, Southern Ethiopia
Maregu Shegaw (BSC) 1, Reta kassa (BSC, MPH )2, Yigrem ali (BSC, MSc)3, Negatu Addissu (BSC, MSc)4
1Depratment of Psychiatry, college of health sciences and Medicine , Dilla University,Ethiopia.
2Depratment of public health, college of health and Medical sciences, Dilla University , Ethiopia.
3Department of psychiatry, college of health sciences and Medicine , Dilla University,Ethiopia
4 Department of Pharmacy, college of health sciences and medicine, Dilla University, Ethiopia
Background: Antiepileptic drugs are effective in the treatment of epilepsy, but poor adherence to medication is major problem to sustained remission and to functional restoration. Poor adherence to treatment is one of many reasons for pharmacological treatment failure and seizure recurrence. Even though there were studies on the magnitude and associated factors of Antiepileptic drugs non-adherence, there is a shortage of published information regarding the prevalence and associated factors of Antiepileptic drugs none-adherence in Ethiopia.
Objective: To assess prevalence and associated factors of antiepileptic drug none-adherence among epileptic patients attending at Dilla University Referral Hospital
Methods: Institutional based cross sectional study design was conducted at Dilla University Referral Hospital from March to May, 2016. A total of 265 individuals was selected by simplerandom sampling method and interviewed by using structured questionnaire. 8 itemMorisky Medication Adherence Scalewas used to assess the prevalence of antiepileptic drug non adherence. Data was coded and exported to SPSS version 20 for analysis.
Results: The prevalence of Antiepileptic’s drug none-adherence in this study was 38.1% and getting medication by payment [AOR2.009, 95%,CI:1.044, 3.868], Patients who did not got health information about(their illness, duration of treatment and drug side effect) [AOR=0.319,95%,CI:0.184,0.534], poor social support [AOR=3.06, 95%, CI: 1.47-6.37], skip dose [AOR=2.462,95%,CI:1.375,4.407], patients who were on treatment for 2-5 years [AOR=1.48, 95%, CI: 0.722,3.035] were found to be significantly associated (p.
Conclusion: The prevalence of antiepileptic drug none-adherence among patients with epilepsy disorder was found 38.1%. Getting medication by payment, did not receive health information about (the illness, duration of treatment, medication side effect), skip dose, on treatment for 2-5 years, and poor social support were found to be the independent predictor of antiepileptic drug none-adherence.
Keywords: Antiepileptic Drugs, prevalence, epileptic patients, Ethiopia
How to cite this article:
Maregu Shegaw (BSC), Reta kassa (BSC, MPH ), Yigrem ali (BSC, MSc), Negatu Addissu (BSC, MSc), Prevalence and Associated Factors of Antiepileptic Drugnonadherence Among Epileptic Patients Attending at Out Patient Departement of Dilla University Referral Hospital, Dilla,gedeo,snnpr, Southern Ethiopia. International Journal of Bioscience and Medicine, 2017; 1:2. DOI: 10.28933/ijbm-2017-07-1401
1. Organization WH. Neurological Disorde.rs: Public Health Challenges: World Health Organization; 2006 2006. 233 p.
2. Stump E. WHO Report: Millions Have Neurological Disorders Worldwide. Neurology Today. 2007;7(7).
3. Organization WHO, others. Atlas: epilepsy care in the world. 2005.
4. O’Donoghue MF, Sander J. The mortality associated with epilepsy, with particular reference to sudden unexpected death: a review. Epilepsia. 1997;38(s11):S15-S9.
5. Osterberg L, Blaschke T. Adherence to medication. New England Journal of Medicine. 2005;353(5):487-97.
6. Hugtenburg JG, Timmers L, Elders PJM, Vervloet M, van Dijk L. Definitions, variants, and causes of nonadherence with medication: a challenge for tailored interventions. Patient Prefer Adherence. 2013;7.
7. Dekker PA, Organization WHO, others. Epilepsy: a manual for medical and clinical officers in Africa. 2002.
8. Sabaté E. Adherence to Long-term Therapies: Evidence for Action: World Health Organization; 2003 2003. 228 p.
9. Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. New England Journal of Medicine. 2011;365(10):919-26.
10. Sander JW. The Use of Antiepileptic Drugs—Principles and Practice. Epilepsia. 2004;45:28-34.
11. H\a akonsen H, Toverud E-L. A review of patient perspectives on generics substitution: what are the challenges for optimal drug use. GaBi J. 2012;1(1):28-32.
12. Neligan A, Bell GS, Johnson AL, Goodridge DM, Shorvon SD, Sander JW. The long-term risk of premature mortality in people with epilepsy. Brain. 2011;134(2):388-95.
13. Kaddumukasa M, Kaddumukasa M, Matovu S, Katabira E. The frequency and precipitating factors for breakthrough seizures among patients with epilepsy in Uganda. BMC neurology. 2013;13(1).
14. Cramer JA, Wang ZJ, Chang E, Powers A, Copher R, Cherepanov D, et al. Healthcare utilization and costs in adults with stable and uncontrolled epilepsy. Epilepsy & Behavior. 2014;31:356-62.
15. Newton CR, Garcia HH. Epilepsy in poor regions of the world. The Lancet. 2012;380(9848):1193-201.
16. Hovinga CA, Asato MR, Manjunath R, Wheless JW, Phelps SJ, Sheth RD, et al. Association of non-adherence to antiepileptic drugs and seizures, quality of life, and productivity: Survey of patients with epilepsy and physicians. Epilepsy & Behavior. 2008;13(2):316-22.
17. Getachew H, Dekema NH, Awol SS, Abdi AA, Mohammed MA. Medication adherence in epilepsy and potential risk factors associated with non adherence in tertiary care teaching hospital in southwest Ethiopia. Gaziantep Medical Journal. 2014;20(1):59-65.
18. Faught RE, Weiner JR, Guérin A, Cunnington MC, Duh MS. Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study. Epilepsia. 2009;50(3):501-9.
19. Jones RM, Butler JA, Thomas VA, Peveler RC, Prevett M. Adherence to treatment in patients with epilepsy: Associations with seizure control and illness beliefs. Seizure. 2006;15(7):504-8.
20. Martins HH, Alonso NB, Guilhoto LMFF, Guaranha MSB, Yacubian EMT. Clinical, Psychosocial and Scientific Note. J Epilepsy. 2009;15(4):192-6.
21. Jin J, Sklar GE, Oh VMS, Li SC. Factors affecting therapeutic compliance: A review from the patient’s perspective. Therapeutics and clinical risk management. 2008;4(1).
22. Organization WHO others. Epilepsy in the WHO Eastern Mediterranean region: bridging the gap2010 2010.
23. Davis KL, Candrilli SD, Edin HM. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia. 2008;49(3):446-54.
24. Brown I, Sheeran P, Reuber M. Enhancing antiepileptic drug adherence: a randomized controlled trial. Epilepsy & Behavior. 2009;16(4):634-9.
25. Chapman SCE, Horne R, Chater A, Hukins D, Smithson WH. Patients’ perspectives on antiepileptic medication: relationships between beliefs about medicines and adherence among patients with epilepsy in UK primary care. Epilepsy Behav. 2014;31:312-20.
26. Carpentier N, Jonas J, Frismand S, Vignal J-P, Rikir E, Baumann C, et al. Direct evidence of nonadherence to antiepileptic medication in refractory focal epilepsy. Epilepsia. 2013;54(1):e20-e3.
27. Kyngäs H. Compliance with health regimens of adolescents with epilepsy. Seizure. 2000;9(8):598-604.
28. Ferrari CMM, de Sousa RMC, Castro LHM. Factors associated with treatment non-adherence in patients with epilepsy in Brazil. Seizure. 2013;22(5):384-9.
29. Liu J, Liu Z, Ding H, Yang X. Adherence to treatment and influencing factors in a sample of Chinese epilepsy patients. Epileptic disorders. 2013;15(3):289-94.
30. Virág L, Murgaš M, Kuželová M. Pharmacotherapeutic adherence and quality of life in paediatric outpatients with epilepsy. Acta Facultatis Pharmaceuticae Universitatis Comenianae. 2012;59(Supplement VI):76-83.
31. Sweileh WM, Ihbesheh MS, Jarar IS, Taha ASA, Sawalha AF, Zyoud SeH, et al. Self-reported medication adherence and treatment satisfaction in patients with epilepsy. Epilepsy & Behavior. 2011;21(3):301-5.
32. Ogboi Sonny J, Babajide F, Ademola O A, Olabunmi O, Agu P U. Evaluation of Factors Influencing Medication Adherence in Patients with Epilepsy in Rural Communities of Kaduna State, Nigeria. Neuroscience & Medicine. 2011;2011.
33. El-Shamaa ET. Factors Contributing To Therapeutic Compliance Of Epileptic Patients And The Suggestive Solutions. Journal of Biology, Agriculture and Healthcare. 2013;3(3):22-35.
34. Mbuba CK, Ngugi AK, Fegan G, Ibinda F, Muchohi SN, Nyundo C, et al. Risk factors associated with the epilepsy treatment gap in Kilifi, Kenya: a cross-sectional study. The Lancet Neurology. 2012;11(8):688-96.
35. Srivastava K, Arora A, Kataria A, Cappelleri JC, Sadosky A, Peterson AM. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence. 2013;7:419-34.
36. Bøen H. Characteristics of senior centre users–and the impact of a group programme on social support and late-life depression. Norsk epidemiologi. 2012;22(2).
37. Kathomi Mbuba C. Epilepsy treatment gap, associated risk factors and intervention strategies in Kilifi, Kenya: University of Basel; 2011.
38. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive Validity of a Medication Adherence Measure in an Outpatient Setting. The Journal of Clinical Hypertension. 2008;10(5):348-54.
39. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Medical care. 1986;24(1):67-74.
40. Nakhutina L, Gonzalez JS, Margolis SA, Spada A, Grant A. Adherence to antiepileptic drugs and beliefs about medication among predominantly ethnic minority patients with epilepsy. Epilepsy & Behavior. 2011;22(3):584-6
This work and its PDF file(s) are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.